News

ANZMTG 01.09 RTN2 TRIAL

Posted: 28th of June, 2016

Do you have any patients who have recently been diagnosed with neurotropic melanoma?

The Australian and New Zealand Melanoma Trials Group (ANZMTG) in conjunction with the Trans-Tasman Radiation Oncology Group (TROG), is conducting an exciting clinical trial for patients diagnosed with primary neurotropic melanoma. 

ANZMTG seeks your support in referring patients to participate in the RTN2 Trial who have recently undergone primary excision surgery for their melanoma lesion (head or neck primaries only).

Clinical care varies around the world. This clinical trial is a unique Australian-led initiative, which will generate evidence to determine the efficacy of post-operative radiation therapy. The results of this trial will aim to make improvements in treatment and management of patients with this diagnosis.  Radiation is often given to treat these patients but there is a lack of evidence in this scenario.

More information can found at anzmtg.org – current trials and  ANZ Clinical Trials Registry - anzctr.org.au (ACTRN12610000478011 / NCT00975520)

Enquiries:
P 61 2 9911 7352
E anzmtg0109@melanoma.org.au

Back
 
Top